Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX) is a healthcare company (diagnostics & research) based in the United States. The share price is $258.20, down 1.53% on the day, which values the company at $28.41B. Price as of 17 Nov 2026, 17:42 UTC, from Yahoo Finance.

Key facts

Share price
$258.20−1.53% today
Market value
$28.41B
P/E ratio
25.7×last 12 months
Forward P/E
21.5×
Dividend yield
1.29%
Funk Score
38/100
Against its own history
Well above its usual priceusual price $165.78
200-week average
$165.9256% above

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Quest Diagnostics Incorporated in more detail

DGX trades at 25.7× its last twelve months' earnings, 21.5× next year's expected earnings, 2.4× sales. Measured against its own history, the price is 56% above what its usual multiples would imply ($165.78) — well above its usual price. It sits 56% above its 200-week average of $165.92.

Over the last five fiscal years Quest Diagnostics Incorporated has compounded revenue 3.2% a year, earnings per share -3.5% a year, free cash flow -3.1% a year. Its Funk Score is 38 out of 100 (financial strength 4.9, profitability 4.7, growth 2.3, value 3.1, each out of 10).

In its favour: Altman Z in the safe zone; Strong Piotroski score.

3 of the superinvestors tracked here hold DGX, including Christopher Davis (1.3% of the portfolio), Jeremy Grantham (co-founder) (1.0% of the portfolio), Pat English (0.9% of the portfolio).

Superinvestors holding DGX

3 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:DGX vs WST (Quest Diagnostics Incorporated vs West Pharmaceutical Services)DGX vs ROIV (Quest Diagnostics Incorporated vs Roivant Sciences)DGX vs PHG (Quest Diagnostics Incorporated vs Koninklijke Philips)DGX vs DXCM (Quest Diagnostics Incorporated vs DexCom)DGX vs LH (Quest Diagnostics Incorporated vs Labcorp Holdings)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Quest Diagnostics Incorporated (DGX): questions and answers

What is DGX's P/E ratio?

Quest Diagnostics Incorporated trades at 25.7× its last twelve months' earnings and 21.5× next year's expected earnings. At its fiscal year-ends over the past 19 years the P/E ranged from 9.7× to 30.4×, with a median of 17.5×.

What is DGX's PEG ratio?

Quest Diagnostics Incorporated's PEG ratio is 1.68 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Quest Diagnostics Incorporated's market cap?

Quest Diagnostics Incorporated is valued at $28.41B at a share price of $258.20.

Is DGX overvalued or undervalued?

Against its own history, DGX is well above its usual price: the price is 56% above the $165.78 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is DGX above its 200-week moving average?

Yes. DGX is 55.6% above its 200-week average of $165.92. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Quest Diagnostics Incorporated growing?

Over the last five fiscal years Quest Diagnostics Incorporated's revenue grew 3.2% a year and its earnings per share -3.5% a year; over ten years revenue grew 3.9% a year.

Cite this page

Funkfolio, “Quest Diagnostics Incorporated (DGX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/DGX

Underlying data: Yahoo Finance; company filings with the SEC.